Mefenamic acid
Clinical data | |
---|---|
Pregnancy category | |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 90% |
Protein binding | 90% |
Metabolism | Hepatic (CYP2C9) |
Elimination half-life | 2 hours |
Excretion | Renal and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C15H15NO2 |
Molar mass | 241.285 g/mol |
WikiDoc Resources for Mefenamic acid |
Articles |
---|
Most recent articles on Mefenamic acid Most cited articles on Mefenamic acid |
Media |
Powerpoint slides on Mefenamic acid |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mefenamic acid at Clinical Trials.gov Trial results on Mefenamic acid Clinical Trials on Mefenamic acid at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mefenamic acid NICE Guidance on Mefenamic acid
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mefenamic acid Discussion groups on Mefenamic acid Patient Handouts on Mefenamic acid Directions to Hospitals Treating Mefenamic acid Risk calculators and risk factors for Mefenamic acid
|
Healthcare Provider Resources |
Causes & Risk Factors for Mefenamic acid |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Mefenamic acid is a non-steroidal anti-inflammatory drug used to treat pain, including menstrual pain. It is commercially available in the US as Ponstel® and internationally by Pfizer as Ponstan®. It is also prescribed as an antipyretic drug. It is typically prescribed for oral administration.
Mefenamic acid decreases inflammation (swelling) and uterine contractions by a still unknown mechanism. However it is thought to be related to the inhibition of prostaglandin synthesis.
Since hepatic metabolism plays a significant role in mefenamic acid elimination, patients with known liver deficiency may be prescribed lower doses. Kidney deficiency may also cause accumulation of the drug and its metabolites in the excretory system. Therefore patients suffering from renal conditions should not be prescribed mefenamic acid.
Side effects
Mefenamic acid is known to cause an upset stomach, therefore it is recommended to take prescribed doses together with food or milk. Instances of drowsiness may also occur. As such, it is recommended to avoid driving or consuming alcohol while taking this medication.
Other known mild side effects of mefenamic acid include headaches, nervousness and vomiting. Serious side effects may include diarrhoea, bloody vomit, blurred vision, skin rash, itching and swelling, sore throat and fever. It is advised to consult a doctor immediately if these symptoms appear while taking this medication.
Sources
- MedlinePlus Drug Information: Mefenamic Acid. Last accessed September 28, 2005.
- Ponstel Pharmacology, Pharmacokinetics, Studies, Metabolism - Mefenamic Acid - RxList Monographs. Last accessed September 28, 2005.
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Non-steroidal anti-inflammatory drugs
- Drugs